Tamadhor Abu-Riash is a licensed pharmacist with a Bachelor in pharmacy and is a certified professional healthcare quality( CPHQ) Practioner. She has over ten years of experience and expertise in pharmaceutical operations, policies and procedures, formulary, healthcare quality and medication safety. She is also an international speaker covering on various pharma topics including drug-drug interaction and the impact of drugs on the quality of life of HCT patients. She is currently pursuing MSc in Advanced Clinical Pharmacy from Queen's University, Belfast.
Member, Pharmacy Research Committee, King Faisal Specialist Hospital, Riyadh
Member, Developing Biological and blood products list and recommendations team
Member, Managing and solving compounding incidents team
Member, Pharmacy command centre
Member, Drive-thru Pharmacy (DTP)
Leader for outpatient pharmacy DTP
Member in the De-prescribing campaign
Member in the project of pharmacy infographics in social media.
Member in the project of expansion of indication for off-label uses in dermatology
Member in various medication utilization evaluation at King Faisal Hospital
Tamadhor is also very active on social media publishing various articles and organising events for the whole pharmacy division in her hospital.
She has also participated in a diverse set of awareness program sessions to help raise the profile of the profession
The primary author for a paper on Drug-drug interaction and its impact on rehabilitation in HCT patients (2021)
Co-investigator - quantifying the Magnitude of Generic-Generic Switching in a Tertiary Care Hospital and its Impact on Patient Comprehension and Safety Feb-June 2019
Co-investigator - effectiveness of Elbasvir/Grazoprevir+- Sofosbuvir in post-transplant patients with chronic hepatitis C virus infection Sep 2018 – ongoing
Co-investigator - the impact of electronic prescribing training and certification program on medication error- junior medical residents Feb 2018- Aug 2019
Poster presentation at Saudi international pharmaceutical science meeting & workshop (Quantifying the magnitude of generic-generic switching in a tertiary care hospital and its impact on patient comprehension and safety) 21-23 January 2020 at Riyadh-KSA and it got the fifth place in the competition.
Poster presentation at American Association for the study of liver disease conference ‘’Elbasvir/Grazoprevir+ Sofosbuvir in HCV genotype1,4 infection after failure of Sofosbuvir based therapy’’.
Poster presentation at American association for the study of liver disease conference (effectiveness of Elbasvir/Grazoprevir+- Sofosbuvir in post-transplant patients with chronic hepatitis C virus infection) Nov2019 at Boston, United States of America
Co-investigator - Effectiveness of Elbasvir/Grazoprevir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Infection Who Have Failed Previous Directly Acting Antiviral Therapy from Dec 2016- ongoing
Co-investigator - Effectiveness of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Renal Impairment at a Tertiary Referral Centre in Saudi Arabia from Nov 2016- ongoing